Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter
Public ClinicalTrials.gov record NCT00115791. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter
Study identification
- NCT ID
- NCT00115791
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Enrollment
- 276 participants
Conditions and interventions
Conditions
Interventions
- RSD1235 Drug
- placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2004
- Primary completion
- May 31, 2005
- Completion
- May 31, 2005
- Last update posted
- Mar 31, 2008
2004 – 2005
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site | Birmingham | Alabama | 35213 | — |
| Investigative Site | Huntsville | Alabama | 35801 | — |
| Investigative Site | Gainesville | Florida | 32610 | — |
| Investigative Site | Orlando | Florida | 32803 | — |
| Investigative Site | Port Charlotte | Florida | 33952 | — |
| Investigative Site | Indianapolis | Indiana | 46202 | — |
| Investigative Site | Shreveport | Louisiana | 71103 | — |
| Investigative Site | Baltimore | Maryland | 21201 | — |
| Investigative Site | Lansing | Michigan | 48910 | — |
| Investigative Site | Petoskey | Michigan | 49770 | — |
| Investigative Site | Saint Paul | Minnesota | 55102 | — |
| Investigative Site | Tupelo | Mississippi | 38801 | — |
| Investigative Site | Holmdel | New Jersey | 07733 | — |
| Investigative Site | Cincinnati | Ohio | 45267 | — |
| Investigative Site | Amarillo | Texas | 79106 | — |
| Investigative Site | Houston | Texas | 77030 | — |
| Investigative Site | Richmond | Virginia | 23249 | — |
| Investigative Site | Tacoma | Washington | 98405 | — |
| Investigative Site | Marshfield | Wisconsin | 544449 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00115791, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 31, 2008 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00115791 live on ClinicalTrials.gov.